Tweet
FDA Warns Consumers Not to Use the Dietary Supplement Lipokinetix.
The Food and Drug Administration (FDA) is warning consumers to stop the use of the product Lipokinetix, marketed as a dietary supplement. The FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix.
Lipokinetix is marketed for weight loss and contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of Lipokinetix. Liver injury developed between 2 weeks and 3 months of Lipokinetix use.
FDA urges consumers to discontinue use of Lipokinetix and consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. Consumers can report the adverse event to FDA's MedWatch hot line at 1-800-FDA-1088 or via the internet at:
The Food and Drug Administration (FDA) is warning consumers to stop the use of the product Lipokinetix, marketed as a dietary supplement. The FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix.
Lipokinetix is marketed for weight loss and contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of Lipokinetix. Liver injury developed between 2 weeks and 3 months of Lipokinetix use.
FDA urges consumers to discontinue use of Lipokinetix and consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. Consumers can report the adverse event to FDA's MedWatch hot line at 1-800-FDA-1088 or via the internet at: